Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
Reads0
Chats0
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
Chemotherapy-induced-peripheral neuropathy, gait and fall risk in older adults following cancer treatment
Timothy Marshall,Timothy Marshall,Genevieve Pinto Zipp,Fortunato Battaglia,Rebecca A. Moss,Stephanie Bryan +5 more
TL;DR: It is suggested that gait speed and step length are key indicators for fall risk, and cancer patients with CIPN may display slower gait velocities, shorter step length, and are at an increased fall risk as indicated by TUG scores.
Journal ArticleDOI
Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
David Mizrahi,Susanna B. Park,Tiffany Li,Hannah C. Timmins,Terry Trinh,Kimberley Au,Eva Battaglini,David Wyld,David Wyld,Robert D. Henderson,Robert D. Henderson,Peter Grimison,Helen Ke,Peter Geelan-Small,Julie Marker,Brian Wall,David Goldstein +16 more
TL;DR: In this paper, the authors identify the association of pretreatment blood-based and clinical factors with CIPN persistence in patients who received paclitaxel or oxaliplatin.
Journal ArticleDOI
A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises
Stefan S. Schönsteiner,Heidi Bauder Mißbach,Axel Benner,Silja Mack,Thomas Hamel,Michael Orth,Bernhard Landwehrmeyer,Sigurd D. Süßmuth,Carolin Geitner,Regine Mayer-Steinacker,Anneliese Riester,Andrea Prokein,Elfriede Erhardt,Jelena Kunecki,Anna Maria Eisenschink,Rainer Rawer,Hartmut Döhner,Elisabeth Kirchner,Richard F. Schlenk +18 more
TL;DR: Whole-body vibration on the background of an IP may improve physical fitness and coordination in patients suffering from CIPN and was significantly associated with a higher reduction of time needed for CRT and significantly improved warm-detection-threshold comparing baseline to follow-up assessment.
Journal ArticleDOI
AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions.
Judith A. Paice,Matthew R. Mulvey,Michael I. Bennett,Patrick M. Dougherty,John T. Farrar,Patrick W. Mantyh,Christine Miaskowski,Brian L. Schmidt,Thomas J. Smith +8 more
TL;DR: A systematic review and synthesis was conducted to provide evidence for the dimensions that comprise this cancer pain taxonomy and future efforts will subject these diagnostic categories and criteria to systematic empirical evaluation of their feasibility, reliability, and validity and extension to other cancer-related pain syndromes.
Journal ArticleDOI
A systematic summary and comparison of animal models for chemotherapy induced (peripheral) neuropathy (CIPN).
Suvarna Gadgil,Mehmet Ergün,Sandra A S van den Heuvel,Selina E I van der Wal,Gert Jan Scheffer,Carlijn R. Hooijmans +5 more
TL;DR: By using effective and robust animal models that mimic the clinical situation as much as possible, the translational value of preclinical study results with respect to the potential of identifying promising treatments for CIPN in the future will prove.
References
More filters
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal ArticleDOI
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti,A. Dimitrios Colevas,Ann Setser,Valerie W. Rusch,David P. Jaques,Volker Budach,Corey J. Langer,Barbara A. Murphy,Richard Cumberlin,C. Norman Coleman,Philip Rubin +10 more
TL;DR: Recent progress in the evolution of adverse effects grading systems is updated and the development of CTCAE v3.0 is reviewed, which represents an international collaboration and consensus of the oncology research community.
Journal ArticleDOI
Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values
Roman Rolke,Ralf Baron,Christoph Maier,Thomas R. Tölle,Rolf-Detlef Treede,Antje Beyer,Andreas Binder,Niels Birbaumer,Frank Birklein,I. C. Bötefür,S. Braune,Herta Flor,Volker Huge,R. Klug,G. B. Landwehrmeyer,Walter Magerl,Christian Maihöfner,C. Rolko,C. Schaub,Andrea Scherens,Till Sprenger,Michael Valet,B. Wasserka +22 more
TL;DR: Application of this standardized QST protocol in patients and human surrogate models will allow to infer underlying mechanisms from somatosensory phenotypes as well as judge plus or minus signs in patients.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more